TY - JOUR T1 - SARS-CoV2- infection as a trigger of humoral response against apolipoprotein A-1 JF - medRxiv DO - 10.1101/2021.02.12.21251298 SP - 2021.02.12.21251298 AU - Sabrina Pagano AU - Sabine Yerly AU - Benjamin Meyer AU - Catherine Juillard AU - NoƩmie Suh AU - Christophe Le Terrier AU - Jean-Pierre Daguer AU - Lluc Farrera-Soler AU - Sofia Barluenga AU - Giovanni Piumatti AU - Oliver Hartley AU - Barbara Lemaitre AU - Christiane S. Eberhardt AU - Claire-Anne Siegrist AU - Isabella Eckerle AU - Silvia Stringhini AU - Idris Guessous AU - Laurent Kaiser AU - Jerome Pugin AU - Nicolas Winssinger AU - Nicolas Vuilleumier Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/02/16/2021.02.12.21251298.abstract N2 - Aims Unravelling autoimmune targets triggered by SARS-CoV-2 infection may provide crucial insights in the physiopathology of the disease and foster the development of potential therapeutic candidate targets and prognostic tools. We want to determine whether SARS-CoV-2 exposure could trigger a humoral response against apolipoprotein A-1 (anti-apoA-1 IgG) through molecular mimicry and assess its relationship to patient prognosis.Methods and Results Anti-Spike domain 1 (SD1) IgGs, anti-apoA-1 IgGs and against mimic peptides, as well as cytokines were assessed by immunoassays on a case-control (n=101), an intensive care unit (ICU; n=126) with a 28-days follow-up, and a general population cohort (n=663) with available samples in the pre and post-pandemic period. Linear sequence homologies and antibodies cross-reactivity between apoA-1, TLR2, and Spike epitopes were identified. Overall, anti-apoA-1 IgG levels were higher in COVID-19 patients or anti-SARS-CoV-2 seropositive individuals than in healthy donors or anti-SARS-CoV-2 seronegative individuals (p<0.0001). Significant and similar associations were noted between anti-apoA-1, anti-SARS-CoV-2 IgG, cytokines, and lipid profile. In ICU patients, anti-SARS-CoV-2 and anti-apoA-1 seroconversion rates displayed similar 7-days kinetics, reaching 82% for anti-apoA-1 seropositivity. C-statistics (CS) indicated that anti-Spike/TLR2 mimic-peptide IgGs displayed a significant prognostic accuracy for overall mortality at 28 days (CS: 0.64; p=0.02). In the general population, SARS-CoV-2 exposure increased baseline anti-apoA-1 IgG levels.Conclusions COVID-19 induces a marked humoral response against the major protein of high-density lipoproteins. As a correlate of poorer prognosis in other clinical settings, such autoimmunity signatures may relate to long-term COVID-19 prognosis assessment and warrant further scrutiny in the current COVID-19 pandemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Swiss Federal Office of Public Health, Swiss School of Public Health (Corona Immunitas research program), the Fondation de Bienfaisance du Groupe Pictet, the Fondation Ancrage, HUG private foundation, and the Center for Emerging Viral Diseases. The De Reuter (grant Nr 657) and the Schmidheiny Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Geneva Ethic Council for Research (CCER) (Protocoles Nr: CCER 2020-00917 and CCER16-363), and written informed consent was obtained by patients prior enrollment. CCER, Rue Adrien-Lachenal 8, 1207 Geneva, Switzerland. ccer@etat.ge.ch All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable request. ER -